News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
Editorial Board
For Authors
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice Between the LinesContemporary ConceptsJournalOncViewPodcastsReadout 360Insights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid LeukemiaBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
Editorial Board
For Authors
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Melanoma
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier

May 16, 2022
Lisa Sprod, PhD, MPH
Publication
Article
OncologyONCOLOGY Vol 36, Issue 5
Volume 36
Issue 5
Pages: 278-279

Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.

Lisa Sprod, PhD, MPH, provides perspective on Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

TABLE 1. Category 1 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

TABLE 1. Category 1 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

Cancer-related fatigue (CRF) is most often evaluated using patient-reported tools, making it subjective in nature. In addition, CRF is multidimensional and often a comorbid condition occurring with mood disorders, pain, and sleep disturbance, among others. Numerous tools have been developed to assess CRF, yet it remains the most common and persistent symptom and/or adverse effect resulting from cancer and its treatment, often lasting many years. In a large multicenter study (n > 3000), Wang et al found that moderate to severe fatigue is common in cancer survivors during active treatment and beyond.1 Other investigators have found that up to 99% of patients with cancer report CRF; and in up to one-third of survivors, fatigue persisted for as long as 10 years after the end of therapy.2

TABLE 2. Category 2 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

TABLE 2. Category 2 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

Despite the high prevalence of CRF, it is still thought to be underreported and undertreated, perhaps in part due to confusion about how to best assess it. With so many survivors of cancer negatively affected by CRF, investigators have focused their efforts on attempting to determine the most effective ways to reduce its impact. Exercise, psychological interventions, and pharmacological treatments have proven to offer some improvement in CRF. As a coauthor on a meta-analysis conducted to determine which intervention was most effective of the 3 listed above, I examined the wide variety of tools used to assess CRF. As an investigator, I have spent countless hours deciding on the best tool to use in my research. Assessment tools vary in their length; the ideal time in which to use them; the recall period; the constructs evaluated; and their sensitivity, reliability, and validity. All of these considerations may leave investigators and clinicians unsure of the best tool for their particular need.

TABLE 3. Category 3 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

TABLE 3. Category 3 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

The authors of the accompanying article have done a phenomenal job providing information that will aid investigators and clinicians in determining the best tool for their needs.3 Specifically, the article provides information that may clarify the best tool for assessing CRF based on factors such as the reason for assessment of CRF (clinical or research) and patient and clinician burden. This article provides a thorough overview of CRF, including prevalence, potential mechanisms, and common comorbidities. Next, the authors describe the challenges associated with choosing the appropriate tool and considerations one should make. With that backdrop, clinicians and investigators are able to utilize the comprehensive tables provided by the authors that categorize tools based on use for screening (Table 1), unidimensional measures (Table 2), or multidimensional measures (Table 3). Information on populations in which the tools have been validated, whether the tools have been translated and/or culturally adapted and validated, the number of items in each tool, the type of rating scales the tools use, the estimated completion time of the tools, and more is available. This article will be one I keep close at hand when reading articles that include CRF as an outcome, and I will certainly rely on it as a I choose CRF measures in my research. In addition, this article may serve as a model that inspires investigators and clinicians to comprehensively review other outcomes with multiple tools for assessment.

References

  1. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120(3):425-432. doi:10.1002/cncr.28434
  2. Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. Cancer Med. 2020;9(21):8053-8061. doi:10.1002/cam4.3413
  3. Gentile D, Beeler D, Wang XS, et al. Cancer-related fatigue measures in integrative oncology: evidence for practice and research recommendations. ONCOLOGY (Williston Park). 2022;36(5):276-287.
Download Issue PDFDownload PDF
Articles in this issue

Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier
Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations
Making Progress in PTCL: Significant Unmet Needs
Making Progress in PTCL: Significant Unmet Needs
Current Treatment of Peripheral T-cell Lymphoma
Current Treatment of Peripheral T-cell Lymphoma
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Expert Commentary On The Product Profile Of Dostarlimab
Expert Commentary On The Product Profile Of Dostarlimab
CRISPR Patent Battle: Beautiful Science, Poor Public Policy
CRISPR Patent Battle: Beautiful Science, Poor Public Policy
Related Videos
Related Content
Advertisement

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

November 21st 2023
Article

In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia

BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia

November 15th 2023
Article

Asher A. Chanan-Khan, MBBS, MD, led a panel discussion surround the use of Bruton tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

November 12th 2023
Article

Sara M. Tolaney, MD, MPH, gives an extensive overview on the current breast cancer landscape and available treatment options.


Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

November 11th 2023
Article

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.

Related Content
Advertisement

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

November 21st 2023
Article

In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia

BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia

November 15th 2023
Article

Asher A. Chanan-Khan, MBBS, MD, led a panel discussion surround the use of Bruton tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

November 12th 2023
Article

Sara M. Tolaney, MD, MPH, gives an extensive overview on the current breast cancer landscape and available treatment options.


Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

November 11th 2023
Article

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.